Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout

The agreement could rise to $900 million if key commercial milestones are met

Union Health Secretary reviews Swachhata Pakhwada at AIIMS Mangalagiri

Punya Salila Srivastava commends sanitation, waste management and infection control measures, while inaugurating a new G+9 undergraduate girls’ hostel

Cupid deposits Rs. 82.88 crore for strategic stake in Baazar Style Retail

The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores

Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells

The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer

The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease